The immune related skin lesions, panniculitis and vitiligo, occurring during treatment with BRAF and MEK inhibitors, are easily detectable and contribute to identify a patient subset destined to obtain a long-term clinical benefit from the therapy. The gene discussed is MAP2K7; the disease is panniculitis.